https://www.fool.com/earnings/call-transcripts/2020/05/08/arrowhead-pharmaceuticals-inc-arwr-q2-2020-earning.aspx
Arrowhead Pharmaceuticals, Inc (ARWR) Q2 2020 Earnings Call Transcript | The Motley Fool
May 9, 2020 - ARWR earnings call for the period ending March 31, 2020.
arrowhead pharmaceuticals incearnings call transcriptq2 2020
https://www.businesswire.com/news/home/20211122006522/en/Arrowhead-Pharmaceuticals-Enters-Exclusive-License-Agreement-with-GSK-for-ARO-HSD
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
Arrowhead Pharmaceuticals and GlaxoSmithKline sign exclusive license agreement for RNAi candidate ARO-HSD against NASH
exclusive license agreementarrowhead pharmaceuticalsenters
https://www.macrotrends.net/stocks/charts/ARWR/arrowhead-pharmaceuticals/eps-earnings-per-share-diluted
Arrowhead Pharmaceuticals EPS - Earnings per Share 2012-2026 | ARWR | MacroTrends
Arrowhead Pharmaceuticals annual and quarterly earnings per share history from 2012 to 2026. Earnings per share can be defined as a company's net earnings or...
earnings per sharearrowhead pharmaceuticalseps20122026
https://www.fool.com/investing/2020/05/24/is-arrowhead-pharmaceuticals-a-buy.aspx
Is Arrowhead Pharmaceuticals a Buy? | The Motley Fool
May 24, 2020 - The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
arrowhead pharmaceuticalsthe motleybuyfool
https://www.biospace.com/press-releases/arrowhead-pharmaceuticals-to-participate-in-may-2025-investor-conferences
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - BioSpace
arrowhead pharmaceuticalsto participatein mayinvestor conferences2025
https://www.benzinga.com/trading-ideas/movers/24/11/42196870/arrowhead-pharmaceuticals-shares-are-on-the-rise-today-whats-going-on
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On? - Arrowhead Pharma...
Nov 26, 2024 - Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with...
on the risearrowhead pharmaceuticals
https://www.fool.com/investing/2023/04/25/why-shares-of-arrowhead-pharmaceuticals-are-up-tue/
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday | The Motley Fool
Apr 25, 2023 - The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
arrowhead pharmaceuticalsthe motleyshares
https://www.biospace.com/arrowhead-pharmaceuticals-to-webcast-fiscal-2023-third-quarter-results
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results - BioSpace
Jul 24, 2023 - Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss its...
arrowhead pharmaceuticalsthird quarterwebcastfiscal2023
https://www.fool.com/investing/2019/12/03/heres-why-arrowhead-pharmaceuticals-is-soaring-tod.aspx
Here's Why Arrowhead Pharmaceuticals Is Soaring Today | The Motley Fool
Dec 3, 2019 - Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.
here sarrowhead pharmaceuticalsthe motley
https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45767953/jim-cramer-arrowhead-pharmaceuticals-doesnt-have-the-horses
Cramer Wonders If Arrowhead Pharmaceuticals Has 'The Horses' - Arrowhead Pharma (NASDAQ:ARWR),...
Jun 4, 2025 - Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."
arrowhead pharmaceuticalsthe horsescramerwonders
https://www.fiercebiotech.com/keyword/arrowhead-pharmaceuticals
Arrowhead Pharmaceuticals | Fierce Biotech
arrowhead pharmaceuticalsfiercebiotech
https://arrowheadpharma.com/en-us
Arrowhead Pharmaceuticals Home | Arrowhead Pharmaceuticals, Inc.
Changing the way diseases are treated, Arrowhead pharmaceuticals uses innovative, scientific methods to discover, develop, and deliver therapies and solutions.
arrowhead pharmaceuticalsinc
https://www.sofi.com/invest/stock/ARWR/
Buy Arrowhead Pharmaceuticals Stock - ARWR Stock Price, Quote & News | SoFi
See real time price charts for ARWR stock, historical data, and recent news. Buy ARWR stock online with no commission fees.
arrowhead pharmaceuticalsprice quotebuystocknews
https://finviz.com/quote?t=ARWR&ty=ea&ta=1&p=d
ARWR - Arrowhead Pharmaceuticals Inc Earnings
ARWR - Arrowhead Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
arrowhead pharmaceuticals incearnings
https://finviz.com/quote?t=ARWR&ty=fc&ta=1&p=d
ARWR - Arrowhead Pharmaceuticals Inc Forecast, Target Price
ARWR - Arrowhead Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
arrowhead pharmaceuticals incforecasttargetprice
https://www.businesswire.com/news/home/20260505950494/en/Arrowhead-Pharmaceuticals-Licenses-Clinical-MASH-Program-Targeting-PNPLA3-to-Madrigal-Pharmaceuticals
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-...
arrowhead pharmaceuticalslicensesclinicalmashprogram
https://www.fool.com/investing/2020/07/08/heres-why-arrowhead-pharmaceuticals-stock-jumped-3.aspx
Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June | The Motley Fool
Jul 8, 2020 - The RNAi treatment developer is clawing its way back after a rough start to 2020.
https://www.businesswire.com/news/home/20260328205340/en/Arrowhead-Pharmaceuticals-Presents-New-Long-Term-Efficacy-and-Safety-Data-for-Plozasiran-Across-a-Spectrum-of-Hypertriglyceridemia-at-the-American-College-of-Cardiologys-75th-Annual-Scientific-Session-and-Expo
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of in...
https://investingnews.com/arrowhead-pharmaceuticals-initiates-phase-1-2a-study-of-aro-dimer-pa-the-first-dual-functional-rnai-therapeutic-for-the-treatment-of-mixed-hyperlipidemia/
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional...
Jan 27, 2026 - - ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies,...
https://www.businesswire.com/news/home/20241118743198/en/Arrowhead-Pharmaceuticals-Submits-New-Drug-Application-to-U.S.-FDA-for-Plozasiran-for-the-Treatment-of-Familial-Chylomicronemia-Syndrome
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...
https://www.biospace.com/arrowhead-pharmaceuticals-presents-new-phase-2-data-of-zodasiran-in-patients-with-mixed-hyperlipidemia
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed...
May 29, 2024 - Arrowhead Pharmaceuticals, Inc. announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed...
https://www.businesswire.com/news/home/20240902885250/en/Arrowhead-Pharmaceuticals-Presents-New-Pivotal-Phase-3-Data-at-ESC-2024-from-PALISADE-Study-of-Plozasiran-in-Patients-with-Familial-Chylomicronemia-Syndrome
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familia...
https://investingnews.com/arrowhead-pharmaceuticals-presents-new-long-term-efficacy-and-safety-data-for-plozasiran-across-a-spectrum-of-hypertriglyceridemia-at-the-american-college-of-cardiology-s-75th-annual-scientific-sessio/
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a...
Mar 28, 2026 - Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500...